Our top pick for
Jaguar Health Inc is a biotechnology business based in the US. Jaguar Health shares (JAGX) are listed on the NASDAQ and all prices are listed in US Dollars. Jaguar Health employs 34 staff and has a trailing 12-month revenue of around 0.00.
|Latest market close||$1.81|
|52-week range||$0.56 - $13.41|
|50-day moving average||$2.23|
|200-day moving average||$3.91|
|Wall St. target price||$14.00|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-1.46|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-10-14)||N/A|
|1 month (2021-09-23)||-25.82%|
|3 months (2021-07-23)||20.67%|
|6 months (2021-04-23)||11.73%|
|1 year (2020-10-23)||586.39%|
|2 years (2019-10-25)||158.65%|
|3 years (2018-10-25)||281.05%|
|5 years (2016-10-25)||101.11%|
|Revenue TTM||$7 million|
|Gross profit TTM||$6.1 million|
|Return on assets TTM||-34.28%|
|Return on equity TTM||-193.3%|
|Market capitalisation||$83.4 million|
TTM: trailing 12 months
There are currently 1.9 million Jaguar Health shares held short by investors – that's known as Jaguar Health's "short interest". This figure is 11.3% down from 2.1 million last month.
There are a few different ways that this level of interest in shorting Jaguar Health shares can be evaluated.
Jaguar Health's "short interest ratio" (SIR) is the quantity of Jaguar Health shares currently shorted divided by the average quantity of Jaguar Health shares traded daily (recently around 2.0 million). Jaguar Health's SIR currently stands at 0.95. In other words for every 100,000 Jaguar Health shares traded daily on the market, roughly 950 shares are currently held short.
However Jaguar Health's short interest can also be evaluated against the total number of Jaguar Health shares, or, against the total number of tradable Jaguar Health shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Jaguar Health's short interest could be expressed as 0.04% of the outstanding shares (for every 100,000 Jaguar Health shares in existence, roughly 40 shares are currently held short) or 0.0411% of the tradable shares (for every 100,000 tradable Jaguar Health shares, roughly 41 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Jaguar Health.
Find out more about how you can short Jaguar Health stock.
We're not expecting Jaguar Health to pay a dividend over the next 12 months.
Jaguar Health's shares were split on a 1:3 basis on 7 September 2021. So if you had owned 3 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Jaguar Health shares – just the quantity. However, indirectly, the new 200% higher share price could have impacted the market appetite for Jaguar Health shares which in turn could have impacted Jaguar Health's share price.
Over the last 12 months, Jaguar Health's shares have ranged in value from as little as $0.555 up to $13.41. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Jaguar Health's is 1.4713. This would suggest that Jaguar Health's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Jaguar Health, Inc. , a commercial stage pharmaceuticals company, focuses on developing prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea. It operates through two reportable segments, Human Health and Animal Health. The company, through its subsidiary, Napo Pharmaceuticals, Inc. , focuses on developing and commercializing proprietary plant-based human gastrointestinal pharmaceuticals from plants harvested responsibly from rainforest areas. It markets Mytesi, a crofelemer 125 mg delayed-release tablet for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. It develops Mytesi for multiple possible follow-on indications, including diarrhea related to targeted cancer therapy; orphan-drug indications for infants and children with congenital diarrheal disorders and short bowel syndrome; supportive care for inflammatory bowel disease; irritable bowel syndrome; and for idiopathic/functional diarrhea, as well as a second-generation proprietary anti-secretory agent is in development for cholera.
Steps to owning and managing ProShares Bitcoin Strategy ETF units.
Everything we know about the The Real Good Food Company IPO, plus information on how to buy in.
Everything we know about the Lulu’s Fashion Lounge Holdings IPO, plus information on how to buy in.
Everything we know about the Allarity Therapeutics IPO, plus information on how to buy in.
Everything we know about the Jupiter Neurosciences IPO, plus information on how to buy in.
Everything we know about the Mainz Biomed IPO, plus information on how to buy in.
Everything we know about the Progressive Care IPO, plus information on how to buy in.
Everything we know about the Desert Peak Minerals IPO, plus information on how to buy in.
Everything we know about the Vaxxinity IPO, plus information on how to buy in.
Everything we know about the Entrada Therapeutics IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.